COVID-19 in patients with B cell immune deficiency.

Vergidis, Paschalis; Levy, Emily R; Ristagno, Elizabeth H; Iyer, Vivek N; O'Horo, John C; Joshi, Avni Y

Vergidis, Paschalis; Levy, Emily R; Ristagno, Elizabeth H; Iyer, Vivek N; O'Horo, John C; Joshi, Avni Y.

Afiliação

Vergidis P; Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Levy ER; Division of Pediatric Critical Care Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA; Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Ristagno EH; Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
Iyer VN; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
O'Horo JC; Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Joshi AY; Division of Pediatric and Adult Allergy and Immunology, Mayo Clinic, Rochester, MN, USA. Electronic address: Joshi.Avni@mayo.edu.

J Immunol Methods ; 510: 113351, 2022 11.

Article em En | MEDLINE | ID: mdl-36087764

Assuntos

COVID-19; Humanos; Profilaxia Pós-Exposição; Estudos Prospectivos; SARS-CoV-2; Vacinação

Palavras-chave

B cell immunodeficiency; COVID-19; PIDD; Prophylaxis; SARS-CoV-2; Vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Immunol Methods Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google